CRISPR Screens in Mechanism and Target Discovery for AML

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Apr 25

PMID 38660246

Authors

Tian Lin

Dan Liu

Zhangchun Guan

Xuan Zhao

Sijin Li

Xu Wang

Rui Hou

Junnian Zheng

Jiang Cao

Ming Shi

Affiliations

Soon will be listed here.

Abstract

CRISPR-based screens have discovered novel functional genes involving in diverse tumor biology and elucidated the mechanisms of the cancer pathological states. Recently, with its randomness and unbiasedness, CRISPR screens have been used to discover effector genes with previously unknown roles for AML. Those novel targets are related to AML survival resembled cellular pathways mediating epigenetics, synthetic lethality, transcriptional regulation, mitochondrial and energy metabolism. Other genes that are crucial for pharmaceutical targeting and drug resistance have also been identified. With the rapid development of novel strategies, such as barcodes and multiplexed mosaic CRISPR perturbation, more potential therapeutic targets and mechanism in AML will be discovered. In this review, we present an overview of recent progresses in the development of CRISPR-based screens for the mechanism and target identification in AML and discuss the challenges and possible solutions in this rapidly growing field.

References

Ley T, Miller C, Ding L, Raphael B, Mungall A, Robertson A . Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013; 368(22):2059-74. PMC: 3767041. DOI: 10.1056/NEJMoa1301689. View

Lagadinou E, Sach A, Callahan K, Rossi R, Neering S, Minhajuddin M . BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013; 12(3):329-41. PMC: 3595363. DOI: 10.1016/j.stem.2012.12.013. View

Skrtic M, Sriskanthadevan S, Jhas B, Gebbia M, Wang X, Wang Z . Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell. 2011; 20(5):674-88. PMC: 3221282. DOI: 10.1016/j.ccr.2011.10.015. View

Pan R, Hogdal L, Benito J, Bucci D, Han L, Borthakur G . Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2013; 4(3):362-75. PMC: 3975047. DOI: 10.1158/2159-8290.CD-13-0609. View

Nair R, Salinas-Illarena A, Baldauf H . New strategies to treat AML: novel insights into AML survival pathways and combination therapies. Leukemia. 2020; 35(2):299-311. DOI: 10.1038/s41375-020-01069-1. View

Brinton L, Sher S, Williams K, Canfield D, Orwick S, Wasmuth R . Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia. Cancers (Basel). 2020; 12(6). PMC: 7352446. DOI: 10.3390/cancers12061574. View

Bao Y, Pan Q, Xu P, Liu Z, Zhang Z, Liu Y . Unbiased interrogation of functional lysine residues in human proteome. Mol Cell. 2023; 83(24):4614-4632.e6. DOI: 10.1016/j.molcel.2023.10.033. View

Nechiporuk T, Kurtz S, Nikolova O, Liu T, Jones C, DAlessandro A . The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells. Cancer Discov. 2019; 9(7):910-925. PMC: 6606338. DOI: 10.1158/2159-8290.CD-19-0125. View

Sharon D, Cathelin S, Mirali S, Di Trani J, Yanofsky D, Keon K . Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response. Sci Transl Med. 2019; 11(516). DOI: 10.1126/scitranslmed.aax2863. View

10.

Hou P, Wu C, Wang Y, Qi R, Bhavanasi D, Zuo Z . A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220. Cancer Res. 2017; 77(16):4402-4413. PMC: 5559306. DOI: 10.1158/0008-5472.CAN-16-1627. View

11.

Wei Y, Xu C, Feng H, Xu K, Li Z, Hu J . Human cleaving embryos enable efficient mitochondrial base-editing with DdCBE. Cell Discov. 2022; 8(1):7. PMC: 8803867. DOI: 10.1038/s41421-021-00372-0. View

12.

Mok B, de Moraes M, Zeng J, Bosch D, Kotrys A, Raguram A . A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing. Nature. 2020; 583(7817):631-637. PMC: 7381381. DOI: 10.1038/s41586-020-2477-4. View

13.

Brinton L, Zhang P, Williams K, Canfield D, Orwick S, Sher S . Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia. J Hematol Oncol. 2020; 13(1):139. PMC: 7574303. DOI: 10.1186/s13045-020-00973-4. View

14.

Liu Y, Cao Z, Wang Y, Guo Y, Xu P, Yuan P . Genome-wide screening for functional long noncoding RNAs in human cells by Cas9 targeting of splice sites. Nat Biotechnol. 2018; . DOI: 10.1038/nbt.4283. View

15.

YATES J, WALLACE Jr H, ELLISON R, HOLLAND J . Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep. 1973; 57(4):485-8. View

16.

Messling J, Agger K, Andersen K, Kromer K, Kuepper H, Lund A . Targeting RIOK2 ATPase activity leads to decreased protein synthesis and cell death in acute myeloid leukemia. Blood. 2021; 139(2):245-255. PMC: 8759535. DOI: 10.1182/blood.2021012629. View

17.

Gu Z, Liu Y, Zhang Y, Cao H, Lyu J, Wang X . Silencing of LINE-1 retrotransposons is a selective dependency of myeloid leukemia. Nat Genet. 2021; 53(5):672-682. PMC: 8270111. DOI: 10.1038/s41588-021-00829-8. View

18.

Chen X, Glytsou C, Zhou H, Narang S, Reyna D, Lopez A . Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment. Cancer Discov. 2019; 9(7):890-909. PMC: 6606342. DOI: 10.1158/2159-8290.CD-19-0117. View

19.

Wang E, Pineda J, Kim W, Chen S, Bourcier J, Stahl M . Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia. Cancer Cell. 2022; 41(1):164-180.e8. PMC: 9839614. DOI: 10.1016/j.ccell.2022.12.002. View

20.

Liu D, Zhao X, Tang A, Xu X, Liu S, Zha L . CRISPR screen in mechanism and target discovery for cancer immunotherapy. Biochim Biophys Acta Rev Cancer. 2020; 1874(1):188378. DOI: 10.1016/j.bbcan.2020.188378. View